Drug Development

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Interim data shows AC Immune's Alzheimer's candidate is safe, but a pivot to boost its power reveals a high-stakes bet on efficacy over speed.

Biotech firm R1 Therapeutics forms a star-studded advisory board to guide its promising kidney disease drug, AP306, into crucial Phase 2b trials.

Skyhawk Therapeutics' oral drug SKY-0515 not only stabilized but appeared to improve key metrics in Huntington's patients, a profound shift in a field long awaiting a breakthrough.

Positive Phase 3 data for BRUKINSA shows a 43% reduction in cancer progression, heralding a chemotherapy-free future for frontline mantle cell lymphoma.

Promising 12-month trial data for SKY-0515 shows it may halt Huntington's, a first for an oral pill. This could disrupt the neuro-market.

A new study reveals how Salipro Biotech's platform makes 'undruggable' membrane proteins accessible, a milestone that could reshape pharmaceutical R&D.

Cytonics completes a key safety trial for its novel osteoarthritis drug, CYT-108. But the real story is a masterclass in strategic innovation.

With Olav Hellebø at the helm, Exonate is advancing a topical eye drop that could end painful eye injections for millions with diabetic retinopathy.

Beyond the dollar figure, Nxera Pharma's latest milestone with AbbVie validates its core technology and marks steady progress in the difficult fight against neurological disease.

With a fresh €6.3M, Munich-based smartbax is developing antibiotics that make bacteria self-destruct, offering new hope against a growing global crisis.

New data on at-home lecanemab injections signals a major shift in Alzheimer's care, promising greater convenience and access for patients and caregivers.

With FDA Priority Review for its at-home therapy Enspryng, Roche is signaling a major disruption in the lucrative Thyroid Eye Disease market.

A new partnership between Finland's Orion Pharma and India's Shilpa Medicare aims to bring a lower-cost cancer therapy to Europe, challenging a blockbuster drug.

A new chemo-free combo from Genmab and AbbVie shows a 60% reduction in disease progression for a tough-to-treat blood cancer, setting a new standard.

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

FibroBiologics secures $3M with a path to $9M, fueling its promising cell therapy pipeline. But is this a strategic masterstroke or a necessary risk?

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.

Artelo Biosciences advances a novel non-opioid painkiller, using AI to map its effects and potentially revolutionize how we treat chronic pain.